Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: In chronic myelogenous leukemia, reciprocal translocation between chromosome 9 and chromosome 22 generates a chimeric protein, Bcr-Abl, that leads to hyperactivity of tyrosine kinase-linked signaling transduction. The therapeutic agent nilotinib inhibits Bcr-Abl/DDR1 and can cross the blood–brain barrier, but its potential impact on neuroinflammatory responses and cognitive function has not been studied in detail. Methods: The effects of nilotinib in vitro and in vivo were assessed by a combination of RT-PCR, real-time PCR, western blotting, ELISA, immunostaining, and/or subcellular fractionation. In the in vitro experiments, the effects of 200 ng/mL LPS or PBS on BV2 microglial cells, primary microglia or primary astrocytes pre- or post-treated with 5 µM nilotinib or vehicle were evaluated. The in vivo experiments involved wild-type mice administered a 7-day course of daily injections with 20 mg/kg nilotinib (i.p.) or vehicle before injection with 10 mg/kg LPS (i.p.) or PBS. Results: In BV2 microglial cells, pre- and post-treatment with nilotinib altered LPS-induced proinflammatory/anti-inflammatory cytokine mRNA levels by suppressing AKT/P38/SOD2 signaling. Nilotinib treatment also significantly downregulated LPS-stimulated proinflammatory cytokine levels in primary microglia and primary astrocytes by altering P38/STAT3 signaling. Experiments in wild-type mice showed that nilotinib administration affected LPS-mediated microglial/astroglial activation in a brain region-specific manner in vivo. In addition, nilotinib significantly reduced proinflammatory cytokine IL-1β, IL-6 and COX-2 levels and P38/STAT3 signaling in the brain in LPS-treated wild-type mice. Importantly, nilotinib treatment rescued LPS-mediated spatial working memory impairment and cortical dendritic spine number in wild-type mice. Conclusions: Our results indicate that nilotinib can modulate neuroinflammatory responses and cognitive function in LPS-stimulated wild-type mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777
Lee, J. W., Lee, Y. K., Yuk, D. Y., Choi, D. Y., Ban, S. B., Oh, K. W., & Hong, J. T. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-37 · Cited by 772
Park, J., Min, J.-S., Kim, B., Chae, U.-B., Yun, J. W., Choi, M.-S., Kong, I.-K., Chang, K.-T., & Lee, D.-S. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2014.10.016 · Cited by 529 · cited 2×
“, ROS, nitric oxide (NO), NADPH oxidase (NOX)] and increases Sod2 mRNA and protein levels in BV2 microglial cells and rat primary microglia [17, 25].”
BackgroundSelf-citationThe role of the medial prefrontal cortex in cognition, ageing and dementia
Jobson, D. D., Hase, Y., Clarkson, A. N., & Kalaria, R. N. (2021) · Brain Communications · doi:10.1093/braincomms/fcab125 · Cited by 338
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
Leszek, J., E. Barreto, G., G|siorowski, K., Koutsouraki, E., Ávila-Rodrigues, M., & Aliev, G. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160202125914 · Cited by 206 · cited 7×
“Superoxide dismutase 2 (SOD2), a major antioxidant enzyme in mitochondria, is reportedly induced in the CNS under various neuroinflammatory conditions [17].”
BackgroundInfluentialPagan, F. L., Hebron, M. L., Wilmarth, B., Torres-Yaghi, Y., Lawler, A., Mundel, E. E., Yusuf, N., Starr, N. J., Anjum, M., Arellano, J., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2019.4200 · Cited by 185 · cited 3×
“, for 12 months) significantly increases the dopamine metabolites homovanillic acid and 3,4-dihydroxyphenylacetic acid in the CSF of AD and PD patients [12, 14].”
BackgroundNilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer’s Disease
Turner, R. S., Hebron, M. L., Lawler, A., Mundel, E. E., Yusuf, N., Starr, J. N., Anjum, M., Pagan, F., Torres‐Yaghi, Y., Shi, W., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25775 · Cited by 126 · cited 3×
“, for 12 months) significantly increases the dopamine metabolites homovanillic acid and 3,4-dihydroxyphenylacetic acid in the CSF of AD and PD patients [12, 14].”
BackgroundZhao, Z., Wang, Y., Zhou, R., Li, Y., Gao, Y., Tu, D., Wilson, B., Song, S., Feng, J., Hong, J.-S., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1728-5 · Cited by 109
La Barbera, L., Vedele, F., Nobili, A., Krashia, P., Spoleti, E., Latagliata, E. C., Cutuli, D., Cauzzi, E., Marino, R., Viscomi, M. T., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102031 · Cited by 98 · cited 1×
“In addition, early and chronic administration of nilotinib in Tg2576 AD model mice reduces Aβ accumulation by blocking DA neuron degradation and preventing morphological changes in the ventral tegmental area (VTA) [57].”
Background
Cited by
Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets
Gao, C., Jiang, J., Tan, Y., & Chen, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01588-0 · Cited by 1,616
Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation
Chen, Y., & Yu, Y. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02853-3 · Cited by 516
Kim, J., Kim, S.-J., Jeong, H.-R., Park, J.-H., Moon, M., & Hoe, H.-S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903309 · Cited by 23
Self-citationLi, Y., Kuang, H., Fan, G., & Yang, X. (2025) · Inflammation · doi:10.1007/s10753-025-02308-2 · Cited by 4
Metadata
- Authors
- Kim, J., Lee, H.-J., Park, J.-H., Cha, B.-Y., & Hoe, H.-S.
- Venue
- Journal of Neuroinflammation
- Published
- 2022-07-15
- Volume
- 19
- Issue
- 1
- Pages
- 187-187
- ISSN
- 1742-2094 (ISSN-L)
- OpenAlex
- W4285491860
- Cited by
- 69
- References
- 11
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling. https://app.cochat.ai/papers/10.1186/s12974-022-02549-0
- The paper
- Kim, J., Lee, H.-J., Park, J.-H., Cha, B.-Y., & Hoe, H.-S. (2022). Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling. Journal of Neuroinflammation. https://doi.org/10.1186/s12974-022-02549-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.